Skip to main content

Table 1 Demographics and main characteristics of the recruited asthmatic patients

From: Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain

 

Reasons for GP consultation

 

Total

A:

Asking for asthma drugs prescription renewal

B:

seeking for medical advice due to symptom worsening

Total (n)

1375

777

598

Male (n, %)

560 (40.7)

313 (40.3)

247 (41.3)

Female (n, %)

815 (59.3)

464 (59.7)

351 (58.7)

Age (mean, SD)

47.2 (17.6)

46.0 (17.7)

48.7 (17.4)

Smoking habits

• non smoker

888 (64.6)

522 (67.2)

366 (61.2)

• smoker

265 (19.3)

130 (16.7)

135 (22.6)

• ex smoker

222 (16,1)

125 (16,1)

97 (16.2)

Mean duration of asthma (years, SD)

12.8 (10.1)

12.6 (9.9)

13.0 (10.4)

Clinical diagnosis (n, %)

604 (43.9)

349 (44.9)

255 (42.6)

Spirometry test (n, %)

771 (56.1)

428 (55.1)

343 (57.4)

Time to last spirometry (years, SD)

2.0 (2.7)

2.2 (3.0)

1.8 (2,2)

Therapy

- Short-acting beta2-agonists (SABA)

814(59.2)

458(58.9)

356(59.5)

- Long-acting beta2-agonists (LABA)

242(17.6)

131(16.9)

111 (18.6)

- Inhaled Corticosteroids (ICS)

397(28.9)

206(26.5)

191(31.9)

- Antihistamines

414(30.1)

230 (29.6)

184 (30.8)

- Leukotriene modifiers

272(19.8)

142 (18.3)

130 (21.7)

- LABA/ICS combinations

793 (57.7)

454(58.4)

339 (56.7)

- Omalizumab

5 (0.4)

3 (0.4)

2 (0.3)

- Systemic corticosteroids

187(13.6)

86 (11.1)

101(16.9)

- Methylxantines

58 (4.2)

21(2.7)

37 (6.2)

- Anticholinergic agents

128 (9.3)

54 (6.9)

74(12.4)

Other(phytodrugs, homeopathicagents,ecc)

20 (1.5)

7 (0.9)

13 (2.2)